Cefotaxime Sodium/Tazobactam Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cefotaxime Sodium/Tazobactam Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cefotaxime Sodium/Tazobactam Sodium can convert its Small molecule drug profile and PBPs x β-lactamase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cefotaxime Sodium/Tazobactam Sodium (query alias: Cefotaxime Sodium/Tazobactam Sodium) |
|---|---|
| Modality / target | Small molecule drug; PBPs x β-lactamase; PBPs inhibitors, β-lactamase inhibitors, Cell wall inhibitors |
| Highest global status | Approved |
| Originator | Nanjing Yoko Pharmaceutical Group Co. Ltd. |
| Active developers | Nanjing YOKO Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Infectious Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06712641 | Phase 4 | Recruiting | 1900 | 30-day mortality |
| ChiCTR2500102245 | Phase 4 | Notyet recruiting | 25 | Bacteriology efficacy |
| TCTR20250410003 | Not Applicable | Recruiting | 134 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
OUTCOMES AFTER 1L TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BELONGING TO STEREOTYPED SUBSET #2, AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC.
Not Applicable; n=445; evaluation: Positive. Reported fields: OS(3-year) = 75.3 % ( 67.5 - 84); OS(3-year) = 91.2 % ( 81.8 - 100); OS(3-year) = 89.1 % ( 81.6 - 97.3)
1886P - Metastatic spread and PD-L1 expression co-determine benefit from pembrolizumab in advanced non-squamous NSCLC
Not Applicable; n=1008; evaluation: Positive. Reported fields: OS: HR = 0.8(95.0% CI, 0.6 - 1.02); HR = 0.7(95.0% CI, 0.5 - 0.85); HR = 0.8(95.0% CI, 0.6 - 1.1); HR = 0.54(95.0% CI, 0.4 - 0.7); HR = 0.46(95.0% CI, 0.3 - 0.6); P-Value = 0.02; OS: HR = 0.8(95.0% CI, 0.6 - 1.02); HR = 0.7(95.0% CI, 0.5 - 0.85); HR = 0.8(95.0% CI, 0.6 - 1.1); HR = 0.54(95.0% CI, 0.4 - 0.7); HR = 0.46(95.0% CI, 0.3 - 0.6); P-Value = 0.02; OS: HR = 0.8(95.0% CI, 0.6 - 1.02); HR = 0.7(95.0% CI, 0.5 - 0.85); HR = 0.8(95.0% CI, 0.6 - 1.1); HR = 0.54(95.0% CI, 0.4 - 0.7); HR = 0.46(95.0% CI, 0.3 - 0.6); P-Value = 0.02
Impact of long-term chemotherapy (CTx) on outcomes in pancreatic ductal adenocarcinoma (PDAC): A real-world UK multi-centre study.
Not Applicable; n=127; evaluation: not stated. Reported fields: Duration of 1st CTx = ≥ 3.58 month ; Duration of 1st CTx = ≥ 3.58 month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cefotaxime Sodium/Tazobactam Sodium addresses Infectious Diseases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PBPs x β-lactamase records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
